Concomitant use of statins and CYP3A4 inhibitors in administrative claims and electronic medical records databases
Authors:
Open Access
- 29 October 2008
- journal article
- Published by Elsevier in Journal of Clinical Lipidology
- Vol. 2 (6) , 453-463
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Risk Management of Simvastatin or Atorvastatin Interactions with CYP3A4 InhibitorsDrug Safety, 2008
- Age-Related Differences in the Prevalence of Potential Drug-Drug Interactions in Ambulatory Dyslipidaemic Patients Treated with StatinsDrugs & Aging, 2007
- Statin Safety: An Assessment Using an Administrative Claims DatabaseThe American Journal of Cardiology, 2006
- Statin Safety and Drug Interactions: Clinical ImplicationsThe American Journal of Cardiology, 2006
- Suboptimal choices and dosing of statins at start of therapyBritish Journal of Clinical Pharmacology, 2005
- Comparative pharmacokinetic interaction profiles of pravastatin, simvastatin, and atorvastatin when coadministered with cytochrome P450 inhibitorsThe American Journal of Cardiology, 2004
- Lack of effect of ketoconazole on the pharmacokinetics of rosuvastatin in healthy subjectsBritish Journal of Clinical Pharmacology, 2003
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- The role of cytochrome P450-mediated drug-drug interactions in determining the safety of statinsExpert Opinion on Pharmacotherapy, 2001
- Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)JAMA, 2001